NBY  Novabay Pharmaceuticals Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-0.04 (-1.61%)

Stability Price

Overvalued by 87.90%

Company Metrics

  • P/E 0
  • P/S 2.67
  • P/B 32.63
  • EPS -7.93
  • Cash ROIC -2,078.99%
  • Cash Ratio 1.62
  • Dividend 0 / N/A %
  • Avg. Vol. 35,895.00
  • Shares 49.63M
  • Market Cap. 8.50M

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


NovaBay Pharmaceuticals Inc.
MarketWatch - Jul 16, 2010
NovaBay Pharmaceuticals Inc. NYSE MKT: NBY. GO. Set Alerts · Find a Broker · Join TD Ameritrade · Market Index · Overview Profile News Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders.
NovaBay Pharmaceuticals, Inc. (NBY) Short Interest Update
EMQ - Jan 13, 2016
NovaBay Pharmaceuticals logo NovaBay Pharmaceuticals, Inc. (NYSE:NBY) was the target of a large decline in short interest during the month of December.
NovaBay Pharmaceuticals, Inc. (NBY) Upgraded to Buy at Zacks Investment Research
IRA Market Report - Jan 24, 2016
NovaBay Pharmaceuticals, Inc. logo Zacks Investment Research upgraded shares of NovaBay Pharmaceuticals, Inc. (NYSE:NBY) from a hold rating to a buy rating in a report issued on Saturday, Marketbeat.com reports. They currently have $3.25 target price ...
News NovaBay Pharmaceuticals Inc.NBY
Wall Street Journal - Feb 11, 2011
News NovaBay Pharmaceuticals Inc.NBY. Significant News Only. 01/11/16; Press Release. NovaBay Pharmaceuticals Expects Fourth Quarter 2015 Avenova Sales to Exceed $1.5 Million.
Recent Broker Updates On NovaBay Pharmaceuticals, Inc. (NBY)
Risers & Fallers - Feb 5, 2016
Recently stock market analysts have updated their consensus ratings on shares of NovaBay Pharmaceuticals, Inc. (NBY).
NovaBay Pharmaceuticals, Inc. (NBY) Falls in Pre-market Before Skyrocketing ...
Independent Reporter - Dec 21, 2015
Shares of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) fell considerably in pre-market trading this morning, before skyrocking after the market opened.
Latest Analysts Reports On NovaBay Pharmaceuticals, Inc. (NBY)
Risers & Fallers - Jan 14, 2016
Recently stock market analysts have updated their consensus ratings on shares of NovaBay Pharmaceuticals, Inc. (NBY).
NovaBay Pharmaceuticals Announces Partnership with ALPHAEON to Bring Avenova ...
Business Wire (press release) - Sep 24, 2015
IRVINE, Calif. & EMERYVILLE, Calif.--(BUSINESS WIRE)--ALPHAEON Corporation and NovaBay Pharmaceuticals, Inc. (NYSE MKT:NBY) announced today that they have formed a partnership that will add NovaBay's breakthrough Avenova to the products ...
NovaBay Pharma inks deal with Alphaeon to sell Avenova on social network ShoutMD - Seeking Alpha
NovaBay Pharma (NBY), ALPHAEON Enter Partnership Covering Avenova - StreetInsider.com
NovaBay Pharmaceuticals Inc.: NovaBay Pharmaceuticals Expects Fourth Quarter ...
The Wall Street Transcript - Jan 11, 2016
NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY) announces that U.S. sales of its prescription Avenova® Lid and Lash Cleanser for the fourth quarter of 2015 are expected to exceed $1.5 million.
Novabay Pharmaceuticals (NBY) Stock Spikes After FDA Approves Disinfection System
TheStreet.com - Jun 4, 2015
NEW YORK (TheStreet) -- Novabay Pharmaceuticals (NBY - Get Report) shares are up 11.46% to 93 cents per share in afternoon trading on Thursday after the biopharmaceutical company announced that it received clearance from the Food and Drug ...
FDA Clears NovaBay Pharmaceuticals' New High-Tech Device, intelli-Case, for ... - Business Wire (press release)